Our CEO Ali Madani spoke with Cade Metz at The New York Times about our landmark achievement in editing the human genome, the launch of OpenCRISPR-1 and what its open-source release could mean for the future of #CRISPR medicines.

Read the full piece👇
nytimes.com/2024/04/22/tec…

Next week our Chief Business Officer Hilary Eaton will be speaking at the MassBio #AlignSummit24 to discuss how we’re leveraging AI to unlock a new generation of genetic medicine: airtable.com/apppacXYqP38v2…

ICYMI, our Chief Business Officer Hilary Eaton discussed how our #GenAI platform will transform drug discovery and development, starting with #CRISPR gene editing.

Check out the full article in Endpoints News 👇

endpts.com/if-you-could-h…

In TechCrunch, Kyle Wiggers covers our founding story, how we’re using #AI to make drug discovery and development more efficient, our first focus on gene editing, and what’s next.

Read the full piece👇
techcrunch.com/2024/03/25/pro…

Thanks Kyle LaHucik for speaking with our founder and CEO Ali Madani and team!

Read more in Endpoints News 👇

endpts.com/if-you-could-h…

A primer on Designing Proteins with Language Models published in Nature Biotechnology by Profluent members. We're expanding the limits of what is possible in bespoke design of biology.

🥳 Profluent has been chosen by FORTUNE in their inaugural #AI Innovators list which highlights the top 50 AI companies! Stay tuned for more updates on how we're pushing the boundaries of AI and Biology to benefit society.
fortune.com/ranking/ai-inn…

The Next Frontier for Large Language Models is Biology. Join us at Profluent to continue pioneering it forward! We have open roles in LLMs, Biology, and more.
forbes.com/sites/robtoews…

AI-enhanced protein design makes proteins that have never existed
nature.com/articles/s4158…

Meet 7 startups in Generative AI by FORTUNE
fortune.com/2023/01/25/gen…